Amaury Durand

Mr. Amaury Durand


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ADAmaury Durand
Amaury Durand
AGAndré Gillibert
André Gillibert
SMSophie Membre
Sophie Membre
LMLisa Mondet
Lisa Mondet
ALAurélie Lenglet
Aurélie Lenglet
AMAurélien Mary
Aurélien Mary
Introduction: Performing pharmacist interventions (PIs) during the medication review helps to improve the quality of care. The acceptance by the physician of these PIs is a good indicator of the quality of this clinical pharmacy activity. The objective of this study was to determine, in the Amiens-Picardie teaching hospital (France), factors of acceptance in a variable environment of activity (central pharmacy, in the care units, computer assisted).Methods: All PIs transcribed by pharmacists on the Act-IP© site between November 2018 and April 2019 were analyzed using a complementary search in patient records. The environment, type, and clinical impact on patient health of each PI was collected. Linear mixed-effects models with a random pharmacist intercept were used to investigate the relationship between PI modalities and their chance of being accepted.Results: A total of 3,100 PIs were traced, of which 2,930 had been followed over time. Of these, 2,930 PIs, 1,504 (51.3%) were performed by a postgraduate pharmacist and 1,426 (48.7%) by a pharmacy resident, 1,623 (55.4%) were performed by verbal exchange, 455 (15.5%) by telephone, 846 (28.9%) by computer software, and 6 (0.2%) by paper. The clinical impact on patient health was major for 976 PIs (33.3%) and vital for 26 PIs (0.9%). According to the Anatomical Therapeutic Chemical Classification (ATC), they were mainly related to anti-infectives (30.3%), the nervous system (18.7%), and blood and blood-forming organs (17.3%). In total, 2,415 PIs (82.4%) were accepted. According to the multivariate model, a PI was more often accepted when it was transmitted orally rather than by software (+27.7%, 95% CI: +23.2 to +32.1%) and when it was transmitted to a medical resident rather than a postgraduate physician (+4.4%, 95% CI: 1.2–7.6%). In these cases, there was a major rather than a moderate clinical impact on patient health (+4.3%, 95% CI: +1.1–+7.6%).Conclusion: This study highlights the importance of the quality of the exchange with the prescriber and the prioritization of high-risk interventions as key points of medication review to improve rate of pharmacist interventions accepted by physician.

1 August 2020 in Neurochirurgie
Verified
Journal Article
Closed access
Bertrand DebonoBertrand Debono
Bertrand Debono
OHO. Hamel
O. Hamel
AGA. Guillain
A. Guillain
ADAmaury Durand
Amaury Durand
MRM. Rué
M. Rué
GDGraciela Isabel Dran
Graciela Isabel Dran

18 December 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ADAmaury Durand
Amaury Durand
DMDavid Mathiron
David Mathiron
SRSébastien Rigaud
Sébastien Rigaud
FDFlorence Djedaini-Pilard
Florence Djedaini-Pilard
FMFrédéric Marçon
Frédéric Marçon
This study investigates the complexation of mefloquine hydrochloride by cyclodextrins to improve its solubility in order to design an oral solution. This approach may enhance the effectiveness of mefloquine, a drug which can be used for malaria prophylaxis and treatment in children. Mefloquine hydrochloride’s solubility was assessed in different buffer solutions, and its quantification was achieved through high-performance liquid chromatography. The complexation efficiency with cyclodextrins was evaluated, and nuclear magnetic resonance (NMR) methods were employed to determine the interactions between mefloquine and cyclodextrins. Mefloquine’s solubility increased when combined with hydroxypropyl-β-cyclodextrin (HP-β-CD) and randomly methylated β-cyclodextrin (RAMEB), with RAMEB being more effective. The drug’s solubility varied across different pH buffers, being higher in acidic buffers. Interestingly, mefloquine’s solubility decreased with a citrate buffer, possibly due to precipitation. The NMR studies highlighted non-covalent interactions between RAMEB, HP-β-CD, and mefloquine, explaining the solubilizing effect via complexation phenomena. Furthermore, the NMR experiments indicated the complexation of mefloquine by all the studied cyclodextrins, forming diastereoisomeric complexes. Cyclodextrin complexation improved mefloquine’s solubility, potentially impacting its bioavailability.

18 October 2021 in International Journal of Pharmacy Practice
Verified
Journal Article
Closed access
ADAmaury Durand
Amaury Durand
SCSarah Cayeux
Sarah Cayeux
BFBloch Frederic
Bloch Frederic
HDHervé Dupont
Hervé Dupont
YSYoussef El Samad
Youssef El Samad
FHFarida Hamdad
Farida Hamdad
Background: The prescription of ceftriaxone should be limited to patients with biliary tract infections and those lacking intravenous access. A specific training session for prescribers about the clinical relevance and economic value of prescribing cefotaxime instead of ceftriaxone might decrease the use of the latter in geriatric medicine. Objectives: To determine the clinical and economic impact of a training session for prescribers on the subsequent prescription of third-generation cephalosporin, that is, the percentage of appropriate prescriptions and the cost of third-generation cephalosporin administration before and after the training session. Methods: In a preliminary observational quasi-experimental, open-label study, appropriateness of cefotaxime and ceftriaxone prescription over a 4-week period immediately before the training session were compared with those during a 4-week period immediately afterwards. Key findings: For 46 patients (29 before the training session and 17 afterwards), the proportion of cefotaxime prescriptions increased (from 3% to 35%; P = 0.007), and the proportion of appropriate prescriptions increased at the start of treatment (from 45% to 76%; P = 0.064) and at the end (from 76% to 88%; P = 0.450). The daily per-patient cost of treatment was €8 for cefotaxime and from €1.63 to €3.42 for ceftriaxone, depending on the administration route. Conclusions: A training session for prescribers was associated with a decrease in ceftriaxone prescriptions encouraging further studies to improve the training session and then evaluate medico-economic impact through randomized clinical trials.

1 September 2020 in Le Pharmacien Hospitalier et Clinicien
Verified
Journal Article
Closed access
ADAmaury Durand
Amaury Durand
LYL. Yang
L. Yang
ALA. Lenglet
A. Lenglet
GDG. Deschasse
G. Deschasse
MBM. Belhout
M. Belhout
FBF. Bloch
F. Bloch

6 July 2023 in Soins Gérontologie
Verified
Journal Article
Closed access
ADAmaury Durand
Amaury Durand
BRBaptiste Routier
Baptiste Routier
LDLaurent Druesne
Laurent Druesne
MDManuella Dubois-Laurent
Manuella Dubois-Laurent
FRFrédéric ROCA
Frédéric ROCA
CCCatherine Chenailler
Catherine Chenailler